Sorted By Test Name - Mayo Medical Laboratories

PLAB
8538
PTSE
61749
age.
Reference Values:
75-140%
Clinical References: 1. Bachman F: Plasminogen-plasmin enzyme system. In Homeostasis and
Thrombosis. Edited by RW Coman, J Hirsh, VJ Marder, et al. Lippencott, 2001, pp 275-320 2.
Demarmels BF, Sulzer I, Stucki B, et al: Is plasminogen deficiency a thrombotic risk factor? Thromb
Haemost 1998;80:167-170 3. Andrews M: The hemostatic system in the infant. In Hematology of Infancy
and Childhood. Vol 1. 4th edition. Edited by DG Nathan, FA Oski. WB Saunders Company, 1993, pp
115-153
Platelet Antibody, Serum
Clinical Information: Platelet antibodies may be allo- or autoantibodies and may be directed to a
wide range of antigenic "targets" carried on platelet cytoplasmic membranes. Platelet alloantibodies are
involved in several clinical situations such as alloimmune platelet refractoriness (APR), neonatal
alloimmune thrombocytopenic purpura (NATP), and posttransfusion purpura (PTP). In these settings, the
antibodies, usually HLA Class I in the case of APR, and platelet-specific antibodies eg, HPA-1a (PLA1)
in the case of NATP or PTP, are found in the patient's plasma and are detected by tests performed on
serum. In contrast, conditions such as idiopathic thrombocytopenic purpura (ITP), systemic lupus
erythematosus (SLE), or sepsis are associated with the presence of excessive platelet associated
immunoglobulin usually IgG. Testing for cell bound platelet antibody is indicated for the diagnosis of
these autoimmune conditions. In some cases of ITP, platelet antibodies can also be found in the patient's
serum but with less frequently than cell bound antibody.
Useful For: Evaluating cases of immune platelet refractoriness, post-transfusion purpura, or neonatal
alloimmune thrombocytopenic purpura
Interpretation: Presence of reactivity to some glycoproteins has no clearly established clinical
significance. Results are based on clinical situation as well as test results. Serum platelet antibody testing
by solid-phase enzyme-linked immunoassay offers more than a positive/negative result. When the
patient's serum is positive, the specific platelet glycoprotein will be identified as well as the probable
specificity. The platelet glycoproteins reported are: IIb/IIIa, Ia/IIa, GPIb/IX. Specificities include the
following: HPA-1a (PL[a1]), HPA-1b (PL[a2]), HPA-3a (BAK[a]/LEK[a]), HPA-3b (BAK[b]), HPA-5b
(Br[a]), HPA-5a (Br[b]). Those specificities listed in parenthesis refer to old nomenclature. In addition,
this assay screens for HLA Class I antibodies, but specificity is not determined.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Kiefel V, Santoso S, Weisheit M, et al: Monoclonal antibody-specific
immobilization of platelet antigens (MAIPA): A new tool for the identification of platelet-reactive
antibodies. Blood 1987;70:1722-1726 2. Moore SB, DeGoey SR: Serum platelet antibody testing:
evaluation of solid-phase enzyme immunoassay and comparison with indirect immunofluorescence. Am J
Clin Pathol 1998;109:190-195
Platinum, Serum
Clinical Information: Cisplatin (cis-diamminedichloroplatinum)(1) and carboplatin
(cyclobutanedicarboxylatoplatinum)(2,3) are used in cancer chemotherapy. Clinical trials demonstrate
schedule-dependent activity of carboplatin in patients with relapsed and refractory acute leukemia.
Patients responding to carboplatin therapy had peak serum platinum concentration in the range of 0.6 to
1.8 mcg/mL. Trough concentrations ranged from 0.1 to 0.4 mcg/mL. Platinum concentrations maintained
>1.8 mcg/mL can induce neutropenia and renal failure if coadministered with nephrotoxic
antibiotics.(1,2) Unexposed individuals should have platinum concentrations